Cancer Treatment News and Research

RSS

Medicinal applications of fullerenes, filled with radioactive material

Fullerenes have attracted considerable attention in different fields of science since their discovery in 1985. Investigations of physical, chemical and biological properties of fullerenes have yielded promising information. It is inferred that size, hydrophobicity, three-dimensionality and electronic configurations make them an appealing subject in medicinal chemistry. Their unique carbon cage structure coupled with immense scope for derivatization make them a potential therapeutic agent.

13 Apr 2011

New experimental drug can help treat peripheral neuropathy in cancer patients

Although oncologists have made great strides in many aspects of cancer treatment, one area that has remained very difficult to treat is peripheral neuropathy, namely pain that can be caused by the cancer or by its treatment.

11 Apr 2011

NEJM: Perspectives from Aaron, Reinhardt, Iglehart, Annas, Chambers and others

This week's New England Journal of Medicine features perspectives from prominent authors on Medicare and Medicaid. NEJM granted KHN permission to excerpt substantial portions of these columns.

8 Apr 2011

Cosmic radiation can increase risk of atherosclerosis in astronauts

Astronauts anticipate more trips to the moon and manned missions to Mars. But exposure to cosmic radiation outside the Earth's magnetic field could be detrimental to their arteries, according to a study by University of Alabama at Birmingham researchers published April 6, 2011, online in the journal Radiation Research.

8 Apr 2011

Powerful natural formula is an effective treatment for men with prostate cancer

Researchers at Indiana University and Methodist Research Institute publish the dramatic effects of a natural formula against prostate cancer. This is the second in-depth study supporting the effectiveness of this formula against the disease.

7 Apr 2011

U.S., Canada research institutions to participate in NCI's Cancer Immunotherapy Trials Network

Research institutions at 27 sites in the U.S. and Canada have been selected to participate in the Cancer Immunotherapy Trials Network, a new initiative in immunotherapy funded by the National Cancer Institute and headquartered at Fred Hutchinson Cancer Research Center.

7 Apr 2011

Breast cancer symposium to discuss on latest advances in research and treatment

The latest advances in both breast cancer treatment and research - including innovations in diagnostic, surgical, chemotherapy and radiation approaches - will be discussed Friday, April 8, 2011, at a breast cancer symposium at the Kimmel Cancer Center at Jefferson in Philadelphia.

7 Apr 2011

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

Circadian Technologies Limited today released data at the American Association for Cancer Research (AACR) annual conference in Orlando, Florida (U.S.A.) demonstrating that its lead anti-cancer therapeutic, VGX-100, significantly inhibits tumour growth and spread in a variety of different mouse models of human cancer.

7 Apr 2011

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating VB-111's potential utility as a targeted cancer treatment.

7 Apr 2011

Superbugs and antibiotic resistance

Health experts come together today (Thursday) to warn that a new form of superbug that gives bacteria the power to resist virtually all known antibiotics is spreading quickly, posing a global health disaster. It is called New Delhi metallobeta-lactamase, or NDM-1 for short. This enzyme destroys carbapenems, an important group of antibiotics used for difficult infections in hospitals, and has been found in a wide variety of bacterial types. British researchers last August reported that infections involving NDM-1 had been found in patients in Bangladesh, India, Pakistan and Britain.

6 Apr 2011

Record number of medicines for various cancers in clinical trials

A record 887 medicines for various of cancers are in clinical trials or awaiting Food and Drug Administration (FDA) review—well over double the number in the pipeline just six years ago, according to a report unveiled today by the Pharmaceutical Research and Manufacturers of America (PhRMA).

6 Apr 2011

Specific lipids in tumours linked to cancer progression and patient survival

Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many cancers. However, the precise molecular composition of lipids in tumours remains generally poorly characterised. Scientists from VTT Technical Research Centre of Finland and the Charité Hospital have found lipids in tumours which are associated with cancer progression.

6 Apr 2011

Soy food does not increase risk of recurrence or death among breast cancer survivors

Soy food consumption did not increase the risk of cancer recurrence or death among survivors of breast cancer, according to the results of a study presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

6 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

Artemisinin or high-pressure oxygen can boost natural cancer remedy

A technique Michael Jackson reportedly used to prolong his youth is showing promise as a way to boost the effectiveness of a natural cancer remedy.

5 Apr 2011

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

The American Cancer Society, the largest non-government, not-for-profit funding source of cancer research in the United States, has awarded 132 national research and training grants totaling $49,213,000 to 85 institutions nationwide in the second of two grants cycles for 2011.

5 Apr 2011

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.

5 Apr 2011

Researchers develop new cancer treatment

Scientists from the School of Pharmacy at Queen's University Belfast and Almac Discovery Ltd have developed a new treatment for cancer which rather than attacking tumours directly, prevents the growth of new blood vessels in tumours, starving them of oxygen and nutrients, thereby preventing their growth.

5 Apr 2011

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Eli Lilly and Company announced results today from two preclinical studies of molecules that target genetic mutations and disable specific signaling pathways that can lead to cancer. The studies evaluated two unique molecules – a JAK2 inhibitor and a Hedgehog inhibitor – with results presented during the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Fla.

5 Apr 2011

Cancer Treatment News and Research

Medicinal applications of fullerenes, filled with radioactive material

New experimental drug can help treat peripheral neuropathy in cancer patients

NEJM: Perspectives from Aaron, Reinhardt, Iglehart, Annas, Chambers and others

Cosmic radiation can increase risk of atherosclerosis in astronauts

Powerful natural formula is an effective treatment for men with prostate cancer

U.S., Canada research institutions to participate in NCI's Cancer Immunotherapy Trials Network

Breast cancer symposium to discuss on latest advances in research and treatment

Circadian's VGX-100 neutralises VEGF-C and inhibits tumour growth in mouse models of human cancers

VBL's VB-111 preclinical data against metastatic cancer presented at AACR meeting

Superbugs and antibiotic resistance

Record number of medicines for various cancers in clinical trials

Specific lipids in tumours linked to cancer progression and patient survival

Soy food does not increase risk of recurrence or death among breast cancer survivors

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Artemisinin or high-pressure oxygen can boost natural cancer remedy

American Cancer Society awards 85 institutions with $49,213,000 for new research, training

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Researchers develop new cancer treatment

Lilly presents results of JAK2, Hedgehog inhibitor preclinical cancer studies at 102nd AACR

Cancer Research eBook

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News